Şener Meryem, Dinçyürek Hüseyin Derya, Totik Nazlı, Bağır Emine Kılıç, Paydaş Semra, Gürkan Emel
Department of Hematology, Faculty of Medicine, Çukurova University, Adana, Turkey.
Mersin City Training and Research Hospital, Hematology Clinic, Mersin, Turkey.
Sci Rep. 2025 Jun 2;15(1):19329. doi: 10.1038/s41598-025-04394-6.
EZH-2 overexpression or mutation is associated with various cancers, and there is a substantial academic literature on the role of EZH-2 and its mutant alleles in the pathogenesis of B-cell non-Hodgkin lymphomas (NHLs). The objective of the study was to examine the expression of EZH-2 in patients with low-grade NHL and to assess the effect of this expression on prognosis. The study included 140 pathologically diagnosed indolent NHL cases that met the established inclusion and exclusion criteria. The study assessed a number of factors, including age at diagnosis, gender, histological type of tumor, region of involvement, clinical stage, treatments received, response to treatment, final disease status, and EZH-2 expression rate. The risk of death is 1.87 times higher in patients with EZH-2 positivity (≥ 30% staining density ) for overall survival, while for disease-free survival, the risk of relapse or disease progression is 1.81 times higher in patients with EZH-2 positivity. EZH-2 positivity has been identified as an independent risk factor that significantly reduces survival, thereby worsening prognosis. These findings suggest that EZH-2 expression may be a valuable prognostic marker in indolent NHLs and may help guide treatment decisions in high-risk patient subgroups.
EZH-2的过表达或突变与多种癌症相关，并且有大量关于EZH-2及其突变等位基因在B细胞非霍奇金淋巴瘤（NHL）发病机制中作用的学术文献。本研究的目的是检测EZH-2在低度NHL患者中的表达，并评估这种表达对预后的影响。该研究纳入了140例经病理诊断的惰性NHL病例，这些病例符合既定的纳入和排除标准。该研究评估了多个因素，包括诊断时的年龄、性别、肿瘤组织学类型、受累部位、临床分期、接受的治疗、对治疗的反应、最终疾病状态以及EZH-2表达率。EZH-2阳性（染色密度≥30%）患者的总生存死亡风险高1.87倍，而对于无病生存，EZH-2阳性患者复发或疾病进展的风险高1.81倍。EZH-2阳性已被确定为一个独立的风险因素，可显著降低生存率，从而使预后恶化。这些发现表明，EZH-2表达可能是惰性NHL中有价值的预后标志物，并可能有助于指导高危患者亚组的治疗决策。
